Medicine and Dentistry
Halofuginone
88%
Pharmacokinetics
44%
Toxicity
44%
Patient
44%
Nausea and Vomiting
33%
Solid Malignant Neoplasm
22%
Recommended Drug Dose
22%
Quinazolinone Derivative
22%
Fatigue
22%
Spectroscopy
11%
Bleeding
11%
Chronic Drug Administration
11%
Antiproliferative Activity
11%
5-HT3 Antagonist
11%
Alkaloid
11%
Therapeutic Procedure
11%
Assay
11%
Analysis
11%
Inpatient
11%
Plasma
11%
Chemistry
Dose
100%
Pharmacokinetics
44%
Toxicity
44%
Once Daily
22%
Maximum Tolerated Dose
22%
Solid
22%
Antiproliferative
11%
Mass Spectrometry
11%
Liquid
11%
Antimetastatic
11%
Twice Daily
11%
Alkaloid
11%
Antiangiogenic
11%
Procedure
11%
Analytical Method
11%
Assay
11%
Sampling
11%
Serotonin 5-HT3 Receptor Antagonist
11%
Pharmacology, Toxicology and Pharmaceutical Science
Halofuginone
88%
Toxicity
44%
Pharmacokinetics
44%
Nausea and Vomiting
33%
Solid Malignant Neoplasm
22%
Maximum Tolerated Dose
22%
Preclinical Study
22%
Antiangiogenic
22%
Quinazolinone Derivative
22%
Fatigue
22%
Bleeding
11%
Serotonin 3 Antagonist
11%
Chemical Engineering
Derivative
22%
Alkaloid
11%